Literature DB >> 7035282

The mechanism of specific suppression in effector T cell clones against tumor-associated transplantation antigens.

H Fujiwara, T Tsuchida, T Mizuochi, T Kohmo, T Hamaoka.   

Abstract

The present study investigates the fate of effector T cell population against tumor-associated transplantation antigens (TATA) of X5563 plasmacytoma in syngeneic mice rendered specifically unresponsive to the TATA. In this tumor system T cell-mediated tumor-specific immunity was induced by intradermal inoculation of viable tumor cells followed by the surgical resection of the tumor (immunization procedure). The intravenous (iv) presensitization of syngeneic hosts with X-irradiated tumor cells abolished the capability of those hosts to develop the tumor-specific immunity after the above appropriate immunization procedure. Spleen cells from the pretreated mice which subsequently received the immunization procedure could not regain the tumor-neutralizing activity after enzymatic treatment with papain. Moreover, lymphoid cells from the pretreated mice could not be stimulated by the immunization procedure even after proteolytic treatment with papain or trypsin, followed by transfer into other recipient mice free of the serum suppressive factor(s). On the other hand, such enzyme treatment was capable of preventing the tolerance induction of dinitrophenyl (DNP)-primed B cells after in vitro pulsing with DNP-D-GL (copolymer of D-glutamic acid and D-lysine) for 2 hr, suggesting that the enzymatic treatment used here was adequate to remove the blocked receptor and any tolerogen. These results suggest that in X5563 plasmacytoma system, the above specific unresponsiveness induced by the iv presensitization with TATA is due to the irreversible inhibition or deletion of effector T cell clones rather than mere effector cell blockade.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7035282

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  4 in total

1.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.

Authors:  H Sano; A Kosugi; S Sano; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Studies on the recovery from tolerance to tumor antigens. I. Bone marrow cells from tolerant hosts are not rendered tolerant, but provide potential to reconstitute tumor-specific effector T cell clones.

Authors:  H Fujiwara; S Sato; A Kosugi; M Fukuzawa; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  The generation of tumor-specific in vivo protective immunity in the tumor mass from mice rendered tolerant to tumor antigens.

Authors:  S Sano; Y Izumi; S Sugihara; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  Studies on the recovery from tolerance to tumor antigens. II. Accelerated recovery of tumor-specific effector T cells in tolerant mice by applying T-T cell interaction mechanism.

Authors:  S Sato; H Fujiwara; A Kosugi; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.